Compare Invesco Preferred ETF (PGX) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Preferred ETF vs Recursion Pharmaceuticals Inc — how do they compare? Invesco Preferred ETF trades at $10.76, while Recursion Pharmaceuticals Inc trades at $2.99 (market cap $1.63B). Which is the better fit depends on your goals.
| PGX | RXRX | |
|---|---|---|
52-Week High | $11.87 | $6.79 |
52-Week Low | $10.79 | $2.84 |
Market Cap | — | $1.63B |
Sector | — | Health |
Enterprise Value | — | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PGX trades at $10.79, down 0.64% on the day, with a bearish technical outlook from moving averages. The ETF shows neutral momentum oscillators. Recent corporate actions include scheduled dividends for mid-2026. News highlights institutional selling and concerns over the fund's risk-return profile in the preferred stock space.
The outlook remains cautious due to structural subordination risks and interest rate sensitivity. Analyst sentiment is negative, citing capped upside and full participation in downturns. Key risks include credit defaults and macroeconomic shifts affecting preferred securities.
Recursion Pharmaceuticals (RXRX) trades at $2.89, down 1.87% with a bearish technical signal despite recent earnings beats. The company shows significant revenue growth challenges with 2025 revenue of $74.26M but massive losses of -$644.76M, resulting in a -851.51% net margin. Analyst sentiment is mixed with 40% buy ratings but a consensus price target of $7.83, representing 171% upside potential from current levels.
While RXRX offers substantial upside based on analyst targets, the stock carries high risk due to persistent losses, negative cash flow from operations, and unproven AI-driven drug discovery platform. The company's heavy reliance on financing activities to fund operations presents ongoing dilution risk, making this suitable only for risk-tolerant investors betting on long-term biotech breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Invesco Preferred ETF
The fund generally will invest at least 80% of its total assets in the components of the index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC selects securities for the index, which is a market capitalization-weighted index designed to measure the performance of the fixed rate US dollar-denominated preferred securities market.
Read more on PGX →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
